drugset
drugset / Trial / NCT05311618

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT05311618 ↗

Phase 1 Unknown 71 enrolled NGM Biopharmaceuticals, Inc Merck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Timeline

Start
2022-05-11
Primary completion
2025-04
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject NGM438 Unknown — Intravenous
Subject Pembrolizumab Monoclonal antibody — Intravenous

Indications

breast cancer cholangiocarcinoma colorectal cancer endocervical carcinoma esophageal cancer gastric cancer head and neck squamous cell carcinoma malignant exocrine pancreas neoplasm melanoma mesothelioma non-small cell lung carcinoma ovarian cancer prostate cancer renal cell carcinoma urinary bladder cancer